Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy

乳腺癌 医学 病态的 内科学 化疗 肿瘤科 新辅助治疗 癌症 完全响应 人口 胃肠病学 环境卫生
作者
Xiaoyan Qian,Meng Xiu,Qing Li,Jiayu Wang,Ying Fan,Yang Luo,Ruigang Cai,Qiao Li,Shanshan Chen,Peng Yuan,Fei Ma,Binghe Xu,Pin Zhang
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:12 被引量:1
标识
DOI:10.3389/fonc.2022.1019925
摘要

Although achieving pathological complete response (pCR) and near-pathological complete response (near-pCR) after neoadjuvant chemotherapy (NAC) in breast cancer predicts a better outcome, some patients still experience recurrence. The aim of our study was to investigate the predictive factors of recurrence in the pCR and near-pCR population.We reviewed 1,209 breast cancer patients treated with NAC between January 2010 and April 2021 in the Cancer Hospital, Chinese Academy of Medical Sciences (CHCAMS). A total of 292 patients achieving pCR and near-pCR were included in our analysis. pCR was defined as ypT0N0/ypTisN0. Near-pCR was defined as ypT1mi/1a/1bN0 or ypT0/isN1mi. Clinical features and follow-up information were collected. Survival and predictive factors of recurrence were analyzed.Of the 292 patients, 173 were pCR and 119 were near-pCR. The median age was 46 years (range, 23-75 years). The predominant tumor subtypes were human epidermal growth factor receptor type 2 (HER2)-positive breast cancer (49.0%) and triple-negative breast cancer (TNBC) (30.8%). The median duration of follow-up was 53 months (range, 9-138 months). A total of 25 (8.6%) patients developed recurrence, with 9 (5.2%) in the pCR group and 16 (13.4%) in the near-pCR group. The vast majority of recurrence occurred within 36 months from onset of NAC. The 5-year recurrence-free survival (RFS) rate of patients achieving pCR was significantly higher than that of patients achieving near-pCR (94.6% vs. 85.6%, p = 0.008). However, the 5-year overall survival (OS) rate between the two cohorts had no statistical difference (94.3% vs. 89.6%, p = 0.304). Clinical N3 (cN3) before NAC was an independent risk factor of recurrence in patients who achieved pCR (p = 0.003) and near-pCR (p = 0.036). Tumor size before NAC, subtypes of breast cancer, and chemotherapy regimens showed no significant association with RFS both for patients who achieved pCR and for those who achieved near-pCR (p > 0.05).cN3 before NAC was an independent risk factor of recurrence in patients who achieved pCR and near-pCR. It is worthwhile to closely monitor patients with cN3, especially in the first 3 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
青松果完成签到,获得积分10
1秒前
yousen完成签到,获得积分20
1秒前
Sid应助Sunwenrui采纳,获得60
1秒前
赘婿应助lw777采纳,获得10
3秒前
4秒前
小蘑菇应助张大英采纳,获得10
4秒前
华仔应助2889580752采纳,获得10
6秒前
嘻嘻完成签到,获得积分10
6秒前
7秒前
丘比特应助科研通管家采纳,获得10
7秒前
领导范儿应助科研通管家采纳,获得10
7秒前
慕青应助科研通管家采纳,获得10
7秒前
7秒前
斯文败类应助科研通管家采纳,获得10
7秒前
7秒前
思源应助科研通管家采纳,获得10
7秒前
田様应助科研通管家采纳,获得10
7秒前
Volcano完成签到,获得积分10
7秒前
无花果应助俏皮的白柏采纳,获得10
8秒前
单薄的夜南应助宁学者采纳,获得10
8秒前
9秒前
9秒前
9秒前
10秒前
空禅yew发布了新的文献求助10
10秒前
华仔应助云辞忧采纳,获得10
12秒前
12秒前
Sunwenrui完成签到,获得积分10
12秒前
12完成签到,获得积分10
14秒前
whoami发布了新的文献求助10
15秒前
15秒前
搜集达人应助TTT0530采纳,获得10
16秒前
张大英发布了新的文献求助10
17秒前
17秒前
18秒前
tassssadar完成签到,获得积分10
18秒前
隐形曼青应助小猴子采纳,获得10
21秒前
22秒前
whoami完成签到,获得积分10
22秒前
Toong发布了新的文献求助10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035